TG1042 Batch Manufacturing Completed - 26 July 2011
Filed with ASX ·
6ix hasn’t read this filing yet.
Prescient Therapeutics Limited on 6ix
Earlier from Prescient Therapeutics
- Virax to acquire advanced cancer platform from Yale Uni
- Response to ASX Aware Letter
- Reinstatement to Official Quotation - 19 November 2013
- Intellectual Property Report Update
- Virax Option to Acquire Exclusive Worldwide Licence
Later from Prescient Therapeutics
- Appendix 4D (31 Dec 2010) - 25 February 2011
- Appendix 4E
- Exclusive License with Transgene for Novel Skin Cancer Immun
- Terms Sheet - Skin Cancer
- Update on VIR201 HIV Vaccine Clinical Trial
Follow Prescient Therapeutics into a list and get an email when it puts out news.
Follow Prescient Therapeutics